Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
IPO Year: 2018
Exchange: NYSE
Website: elanco.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/15/2026 | $30.00 | Buy | Citigroup |
| 1/22/2026 | Neutral → Overweight | Piper Sandler | |
| 12/9/2025 | $30.00 | Overweight | Barclays |
| 11/21/2025 | $27.00 | Overweight | KeyBanc Capital Markets |
| 11/19/2025 | $25.00 | Hold → Buy | Argus |
| 10/7/2025 | $24.00 | Neutral → Overweight | Analyst |
| 7/17/2025 | $18.00 | Market Perform → Outperform | Leerink Partners |
| 6/26/2025 | Mkt Perform → Outperform | William Blair | |
| 12/9/2024 | $18.00 | Buy | UBS |
| 12/2/2024 | $14.00 | Market Perform | Leerink Partners |
SD - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
10-Q - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
DEFA14A - Elanco Animal Health Inc (0001739104) (Filer)
DEF 14A - Elanco Animal Health Inc (0001739104) (Filer)
SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citigroup initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $30.00
Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight
Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00
KeyBanc Capital Markets initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $27.00
Argus upgraded Elanco Animal Health from Hold to Buy and set a new price target of $25.00
Analyst upgraded Elanco Animal Health from Neutral to Overweight and set a new price target of $24.00
Leerink Partners upgraded Elanco Animal Health from Market Perform to Outperform and set a new price target of $18.00
William Blair upgraded Elanco Animal Health from Mkt Perform to Outperform
UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00
Leerink Partners initiated coverage of Elanco Animal Health with a rating of Market Perform and set a new price target of $14.00
Fastest customizable press release news feed in the world
INDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to prioritize spending on their pets, underscoring the robust and resilient nature of the industry. According to Elanco's latest survey of 1,409 U.S. pet owners conducted May 29-31, even with rising costs across spending categories including higher gas prices, pet health and wellness remain an absolute priority for pet owners as a protected budget item.Stable Expectations for Pet Owner Spend:
Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics todayBefrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight restrictions, and lasts 6 to 8 weeks, compared to the 4 to 8 weeks of the current market incumbent, lokivetmabStarts controlling itch within 24 hours and is given as an in-clinic injectionSelect Early Experience Program veterinarians are already using Befrena in clinical practice and seeing positive outcomesMeet Beaux, Penelope and Zephyr, the first early experience patients to receive Befrena and follow their jo
INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, May 27, Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will participate in a fireside chat at the Stifel 2026 Jaws & Paws Conference at 8:00 a.m. ET.On Tuesday, June 2, Jeff Simmons, president and CEO will present at the William Blair 46th Annual Growth Stock Conference at 3:20 p.m. CT.Live audio webcasts will be available in the "Events and Presentations
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio TargetFirst Quarter 2026 Financial Results:Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growthReported Net Income of $57 million, Adjusted Net Income of $204 millionAdjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5%Reported EPS of $0.11, Adjusted EPS of $0.40Net leverage ratio of 3.5x Adjusted EBITDAFull Year 2026 Guidance:Raising innovation revenue target to $1.2 billionRaising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growthRaising Adjusted EBITDA to $975 million to $1,005 million, a year-over-y
/C O R R E C T I O N – Elanco Animal Health/ In the news release, Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock, issued 27-Apr-2026 by Elanco Animal Health over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock Action Prepares Veterinarians and Livestock Prod
Action Prepares Veterinarians and Livestock Producers with Prevention and Treatment Options Prior to Fly Being Detected in the U.S.Federal agencies grant emergency authorizations for New World screwworm in livestock, reinforcing Elanco's leadership in livestock health innovations Actions underscore the commitment of the U.S. Food and Drug Administration, U.S. Environmental Protection Agency, and U.S. Department of Agriculture to act swiftly against emerging animal health threats Early detection and immediate treatment of open wounds on livestock is critical to prevention of New World screwworm myiasis in individual animals and rapid spread of the pestAn effective fly and tick control regime
National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno. "I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth." Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ:AC
INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.asp
Breaks the flea lifecycle* with Pyriproxyfen, an insect growth regulator, preventing fleas from reinfesting the dogAdjustable collar fits comfortably and securely on a dog of any sizeStrengthens Elanco's 25-year Advantage brand familyAvailable at pet specialty, dollar, grocery and mass retailers, with a suggested retail price below $25**INDIANAPOLIS, April 9, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the launch of its Advantage™ Collar for Dogs, a new product providing long-lasting protection against two parasites that don't take a season off – fleas and ticks. Designed for dogs and puppies 12 weeks of age and older, this dog collar kills and repels fl
Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
Live Leadership Updates
National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno. "I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth." Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ:AC
MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo
NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior
The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are
GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi
Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen
New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthcare industries. She has held senior leadership positions at IDEXX Labora
GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE:ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short term serving as our interim general counsel combined with her robust experience made it clear that she was the right person for this role," said Jeff Simmons,
Calling all Veterinarians and Pet Lovers - Take the "Defend Puppies. Defeat Parvo." Pledge Today to Save Puppies from Deadly Canine Parvovirus GREENFIELD, Ind., Jan. 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today launched the first-of-its-kind, multi-year campaign to save 1 million puppies from unnecessary death from the highly contagious canine parvovirus (parvo). The Defend Puppies. Defeat Parvo. mission seeks to conquer a virus that, without timely and aggressive care, has a mortality rate as high as 91%1. An estimated 900 dogs are diagnosed with parvo daily2 in the U.S. – mostly unvaccinated puppies. Yet Elanco research revealed only 44% of dog owners know
Ziff Davis, Inc. (NASDAQ:ZD), today announced the appointment of Kirk McDonald to its Board of Directors, effective November 15, 2023. McDonald is a highly accomplished executive with extensive experience and a career spanning more than three decades in media, technology, and advertising. "We are thrilled to welcome Kirk to our Board of Directors," said Ziff Davis Board Chair Sarah Fay. "As an industry veteran known for his business leadership, he will be an asset to Ziff Davis." McDonald serves as CEO of GroupM North America, a leading media investment agency. He announced that he will leave the role at year end. Prior to this, he was Chief Business Officer of Warner Media's Xandr when
This live feed shows all institutional transactions in real time.
Live finance-specific insights
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio TargetFirst Quarter 2026 Financial Results:Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growthReported Net Income of $57 million, Adjusted Net Income of $204 millionAdjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5%Reported EPS of $0.11, Adjusted EPS of $0.40Net leverage ratio of 3.5x Adjusted EBITDAFull Year 2026 Guidance:Raising innovation revenue target to $1.2 billionRaising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growthRaising Adjusted EBITDA to $975 million to $1,005 million, a year-over-y
INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.asp
Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre
INDIANAPOLIS, Jan. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern Standard Time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-
Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to <3x in 2027, with a long-term target of 2.0x to 2.5x.Expects innovation revenue contribution of approximately $1.1 billion in 2026, with aims to double revenue from 'Big 6' blockbuster potential products by 2028.Discusses 10+ major innovation products in development phase with 5-6 blockbuster-potential approvals expected between 2026 and 2031. Two in-house technology development platforms
GREENFIELD, Ind., Oct. 1, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2025 financial results on Wednesday, November 5, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported
GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d
Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported
GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau